Pamisel, Top Search Ranking... Stock Price -1.69%

As of 1:32 PM on the 17th, Pamicell is trading at 20,300 KRW, down 1.69% from the previous day. This represents a 15.77% decline compared to May 29. Pamicell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.

Today, foreigners have a tentative net purchase of 68,316 shares of Pamicell, and institutions have a net purchase of 1,000 shares. Over the past five days, individual investors have net purchased 173,645 shares, while foreigners and institutions have net sold 189,199 shares and net purchased 40,933 shares, respectively.

On June 12, Pamicell was a market topic with the news of "Phase 2 clinical trial approval for erectile dysfunction stem cell therapy" leading to a strong performance.

[Table] Foreigners and Institutions Net Trading Volume (Unit: shares)

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.